Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor γ by inhibition of the c-Jun NH2-terminal kinase pathway

Diabetes

Volumn 56, Issue 7, 2007, Pages 1865-1871

  Díaz Delfín, Julieta ^b   Morales, Mònica ^b   Caelles, Carme ^a  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE TRANSPORT; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; CHROMANS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 34347369726     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1293     Document Type: Article

References (43)

1. Scheen AJ: Obesity and diabetes. In The Management of Obesity and Related Disorders. Kopelman PG, Ed. London, Martin Dunitz, 2001, p. 11-44
2. Flier JS: The missing link with obesity? Nature 409:292-293, 2001
3. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668, 1996
4. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 410:37-40, 2001
5. 307. J Biol Chem 275:9047-9054, 2000
6. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002
7. Bennett BL, Satoh Y, Lewis AJ: JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 3:420-425, 2003
8. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka T, Matsuhisa M, Kajimoto Y, Ichijo H, Yamasaki Y, Hori M: Possible novel therapy for diabetes with cell-permeable JNK-inhibitor peptide. Nat Med 10:1128-1132, 2004
9. Ammendrup A, Maillard A, Nielsen K, Andersen NA, Serup P, Madsen OD, Mandrup-Poulsen T, Bonny C: The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic β-cells. Diabetes 49:1468-1476, 2000
10. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF: Cell-permeable peptide inhibitors of JNK. Diabetes 50:77-82, 2001
11. Waeber G, Delplanque J, Bonny C, Mooser V, Steinmann M, Widmann C, Maillard A, Miklossy J, Dina C, Hani EH, Vionnet N, Nicod P, Boutin P, Froquel P: The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 24:291-295, 2000
12. Diamant M, Heine RJ: Thiazolidinediones in type 2 diabetes mellitus. Drugs 63:1373-1405, 2003
13. Peraldi P, Xu M, Spiegelman BM: Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869, 1997
14. Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O, Kobayashi M: Pioglitazone ameliorates tumor necrosis factor-α-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ. Diabetes 50:1083-1092, 2001
15. Miles PDG, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM: TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46:1678-1683, 1997
16. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52:1943-1950, 2003
17. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2001
18. Leiter LA: β-Cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med 22:963-972, 2005
19. Ogawa J, Takahashi S, Fujiwara T, Fukushige J, Hosokawa T, Izumi T, Kurakata S, Horikoshi H: Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci 65:1287-1296, 1999
20. Moller DE, Berger JP: Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes 27:S17-S21, 2003
21. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 83:835-839, 1995
22. Rosen ED, Spiegelman BM: PPAR-γ: a nuclear receptor of metabolism, differentiation and cell growth. J Biol Chem 276:37731-37734, 2001
23. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812, 1995
24. 2 metabolite binds peroxisome proliferators-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819, 1995
25. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J: A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Cell 8:737-747, 2001
26. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Corre ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferators-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
27. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195, 1996
28. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P: Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 145:667-678, 2004
29. Caelles C, Morales M: Assays to measure stress-activated mitogen-activated protein kinase activity. In Apoptosis Methods and Protocols. Brady HJM, Ed. Totowa, NJ, Humana Press, 2004, p. 145-156
30. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956, 1995
31. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM: A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 275:1873-1877, 2000
32. Maedler K, Sergeev P, Ris F, Oberholzer J, Joler-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY: Glucose-induced beta cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860, 2002
33. Kerouz NJ, Hörsch D, Ponsm S, Kahn CR: Differential regulation of insulin receptor substrate-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 100:3164-3172, 1997
34. Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T: Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-α-deficient mice on a highfat diet. Diabetes 53:2844-2854, 2004
35. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82, 1998
36. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998
37. Caelles C, González-Sancho JM, Muñoz A: Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11:3351-3364, 1997
38. Bruna A, Nicolàs M, Muñoz A, Kyriakis JM, Caelles C: Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J 22:6035-6044, 2003
39. Aouadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binétruy B, Bost F: Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 55:281-289, 2006
40. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410, 1997
41. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutation in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883, 2001
42. Camp HS, Tafuri SR, Leff T: c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-g1 and negatively regulates its transcriptional activity. Endocrinology 140:392-397, 1999
43. Kaneto H: The JNK pathway as a therapeutic target for diabetes. Expert Opin Ther Targets 9:581-592, 2005